Skip to main content

Advertisement

Table 1 List of FDA-approved kinase inhibitors and their drug targets

From: Kinase-targeted cancer therapies: progress, challenges and future directions

Drug target Protein substrate Drug
ALK Tyrosine Crizotinib, Ceritinib, Alectinib, Brigatinib
BCR–Abl Tyrosine Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib
B-Raf Serine/threonine Vemurafenib, Dabrafenib
BTK Tyrosine Ibrutinib
CDK family Serine/threonine Palbociclib, Sorafenib, Ribociclib
c-Met Tyrosine Crizotinib, Cabozantinib
EGFR family Tyrosine Gefitinib, Erlotinib, Lapatinib, Vandetanib, Afatinib, Osimertinib
JAK family Tyrosine Ruxolitinib, Tofacitinib
MEK1/2 Dual specificity Trametinib
PDGFR α/β Tyrosine Axitinib, Gefitinib, Imatinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib
RET Tyrosine Vandetanib
Src family Tyrosine Bosutinib, Dasatinib, Ponatinib, Vandetanib
VEGFR family Tyrosine Axitinib, Lenvatinib, Nintedanib, Regorafenib, Pazopanib, Sorafenib, Sunitinib